TY - JOUR
T1 - Statins and portal hypertension
T2 - a systematic review and meta-analysis of randomized controlled trials
AU - Jamialahmadi, Tannaz
AU - Reiner, Željko
AU - Riahi, Maryam Matbou
AU - Emami, Seyed Ahmad
AU - Tayarani-Najaran, Zahra
AU - Salehabadi, Sepideh
AU - Kesharwani, Prashant
AU - Al-Rasadi, Khalid
AU - Sahebkar, Amirhossein
N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
PY - 2023/9/18
Y1 - 2023/9/18
N2 - BACKGROUND: Statins are primarily used to decrease elevated LDL-cholesterol and thus prevent atherosclerotic cardiovascular disease. Portal hypertension is one of the most important complications of chronic liver disease. Several studies indicated that statins might be beneficial for portal hypertension as well but there is still no clear answer whether this is true or not.METHODS: A literature search of the major databases was performed to find eligible randomized controlled trials (RCTs) analyzing the effect of statins on portal hypertension from inception to February 5th, 2021. Six RCTs with 442 patients who received statin or statin plus carvedilol were finally included. Meta-analysis was performed using the Comprehensive Meta-Analysis V2 software.RESULTS: Reduction of portal hypertension after statin treatment was not significant (WMD: -0.494, 95% CI: -1.239, 0.252, p=0.194; I2:0%). The reduction of portal hypertension was robust in the leave-one-out sensitivity analysis.CONCLUSION: Treatment with statins did not decrease significantly portal hypertension.
AB - BACKGROUND: Statins are primarily used to decrease elevated LDL-cholesterol and thus prevent atherosclerotic cardiovascular disease. Portal hypertension is one of the most important complications of chronic liver disease. Several studies indicated that statins might be beneficial for portal hypertension as well but there is still no clear answer whether this is true or not.METHODS: A literature search of the major databases was performed to find eligible randomized controlled trials (RCTs) analyzing the effect of statins on portal hypertension from inception to February 5th, 2021. Six RCTs with 442 patients who received statin or statin plus carvedilol were finally included. Meta-analysis was performed using the Comprehensive Meta-Analysis V2 software.RESULTS: Reduction of portal hypertension after statin treatment was not significant (WMD: -0.494, 95% CI: -1.239, 0.252, p=0.194; I2:0%). The reduction of portal hypertension was robust in the leave-one-out sensitivity analysis.CONCLUSION: Treatment with statins did not decrease significantly portal hypertension.
UR - https://www.mendeley.com/catalogue/a8eda1bc-9ced-3bd1-9f5f-bd4a0360b3fd/
U2 - 10.2174/0929867331666230918114451
DO - 10.2174/0929867331666230918114451
M3 - Article
C2 - 37723637
SN - 0929-8673
VL - 31
JO - Current Medicinal Chemistry
JF - Current Medicinal Chemistry
ER -
